Jeena Sikho Lifecare
NSE: JSLLBSE: 544476
₹ 347.80▲ 2.8 (+0.81%)28 Oct, 03:29 pm IST
- Market cap
- ₹ 4,260 Cr.
- P/E
- 17.9x
- P/B
- 9.3x
- 52-week range
- 331.45 – 835
- ROE
- 60%
- ROCE
- 71%
- Dividend yield
- 1.3%
- Debt / equity
- 0.27
- Sector
- Leisure Services
- Industry
- Wellness
- Listed on
- NSE, BSE
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Wellness: 3 companies →Jeena Sikho Lifecare against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)17.9 against a typical 147.1: cheaper than most peers (1st = cheapest).1st of 3
- Sales growth+28.7% against a typical +28.7% from a year earlier.2nd of 3
- Share price, 3 months−38.9% against a typical −13%.3rd of 3
- Size₹ 4,259.9 Cr. market value against a typical ₹ 426.2 Cr. (1st = largest).1st of 3
Research by Minerva Capital Research Solutions
Our research team's work on Jeena Sikho LifecareAlso covered in
Company note · 11 Feb 2026 · Free
Company note · 19 Oct 2025 · Free
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 7 Aug 2026 | Financial Results | To consider and approve the Unaudited financial results for the quarter ended June 30, 2026 |
| 30 May 2026 | Financial Results/Dividend | To consider and approve the Audited Financial Results (Standalone & Consolidated) for the quarter and year ended 31st March, 2026 and recommend dividend, if any, for the financial year ended 31st March, 2026 |
| 7 Feb 2026 | Financial Results | To consider and approve the Unaudited Quarterly Financial Results (Standalone & Consolidated) for the period ended December 31, 2025 |
| 6 Nov 2025 | Financial Results | To consider and approve the Un-Audited Financial Results (Standalone and Consolidated) along with the Limited Review Report for the quarter ended September 30, 2025 |
| 27 Aug 2025 | Other business matters | 1. To consider and approve the proposal for Employee Stock Option Scheme 2025 in terms of SEBI (Share Based Employee Benefits and Sweat Equity) regulations, 2021.2. To consider any other matter, with the permission of the Chairperson. |
| 14 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 100 | 114 | 116 | 139 | 174 | 190 | 222 | 216 | 224 |
| Expenses | 75 | 74 | 86 | 93 | 96 | 98 | 121 | 138 | 132 |
| Operating Profit | 25 | 40 | 30 | 46 | 79 | 92 | 101 | 78 | 92 |
| OPM % | 25% | 35% | 26% | 33% | 45% | 48% | 45% | 36% | 41% |
| Other Income | 3 | 3 | 0 | 0 | 1 | 1 | 3 | 4 | 14 |
| Interest | 1 | 2 | 4 | 3 | 2 | 4 | 3 | 4 | 3 |
| Depreciation | 5 | 6 | 8 | 9 | 10 | 10 | 11 | 16 | 15 |
| Profit before tax | 21 | 35 | 18 | 34 | 69 | 79 | 89 | 62 | 87 |
| Tax % | 23% | 25% | 26% | 25% | 25% | 25% | 25% | 26% | 25% |
| Net Profit | 16 | 27 | 13 | 25 | 51 | 59 | 67 | 45 | 66 |
| EPS in Rs | 1.3 | 2.14 | 1.06 | 2.04 | 4.13 | 4.73 | 5.37 | 3.65 | 5.28 |
Growth and returns
Compounded yearly rates over each period.
Compounded Sales Growth
- 10 Years
- —
- 5 Years
- 43%
- 3 Years
- 58%
- TTM
- 57%
Compounded Profit Growth
- 10 Years
- —
- 5 Years
- 85%
- 3 Years
- 88%
- TTM
- 103%
Stock Price CAGR
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 65%
- TTM
- —
Return on Equity
- 10 Years
- —
- 5 Years
- 48%
- 3 Years
- 50%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
P/E 17.9xEPS (12 months) ₹ 19.03Median P/E 49.7x
P/E (times)EPS (₹)
Prices are delayed and for information only. Nothing on this page is investment advice.